Clinical Trials Using Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

    The purpose of this study is to determine the safety profile, maximum tolerated dose (MTD) and / or recommended phase 2 dose (RP2D) of single agent ISB1302 in subjects with HER2-positive metastatic breast cancer who have been treated with all known therapies known to confer clinical benefit.
    Location: 2 locations